Drug Profile
Research programme: neurodegenerative disorder therapeutics - Celgene Corporation/Evotec
Alternative Names: BMSxxxLatest Information Update: 13 Jul 2023
Price :
$50
*
At a glance
- Originator Evotec AG; Harvard Stem Cell Institute
- Developer Celgene Corporation; Evotec SE
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease
Most Recent Events
- 11 Jul 2023 Bristol Myers Squibb enters into an exclusive global license agreement with Evotec SE for selected late-stage neurodegeneration discovery programmes that were developed and progressed within the collaboration
- 28 Mar 2023 Evotec SE extended and expanded its strategic neurodegeneration partnership with Bristol Myers Squibb
- 08 Oct 2021 Evotec expands its research and development collaboration with Bristol-Myers Squibb for inclusion of additional cell lines in the iPSC platform